Ampio Pharmaceuticals Developing a Promising Pipeline
After a fairly quiet Thanksgiving week, Monday morning has produced a number of significant stories in the biotech world. One stock that is seeing some nice gains is Ampio Pharmaceuticals (NYSEMKT:AMPE).
Ampio Pharmaceuticals is a biopharmaceutical firm that develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction, and CNS disease. One of Ampio’s key strategies is to actively explore partnership, licensing, and other collaboration opportunities to maximize the company’s product development programs.
There are three current candidates in Ampio Pharmaceuticals’ product pipeline.
- Zerfane: Used to treat sexual dysfunction
- Optina: Used to treat diabetic retinopathy and diabetic macular edema
- Ampion: Used to treat osteoarthritis of the knee
On Monday morning, Ampio Pharmaceuticals received Food and Drug Administration confirmation that the Spring Study could be considered pivotal. The Spring Study, also known as AP-003-A, was given the approval because of the fact that the study had an adequate number of enrolled subjects (329) and because it was well controlled through its use of normal saline.